

Phase I trial: MM-120-101

Submission date 14/05/2024	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 21/05/2024	Overall study status Deferred	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 13/01/2026	Condition category Other	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Contact information

Type(s)

Public, Scientific, Principal investigator

Contact name

Dr David Gregory

Contact details

11 Tiger Court, Kings Drive Prescott
Liverpool
United Kingdom
L34 1BH
+44 (0)151 4824700
davidgregory@macplc.com

Type(s)

Scientific

Contact name

None Jo Brady

Contact details

Senior Consultant
DLRC Regulatory Consultancy
Suite 201, The Nexus Building, Broadway
Letchworth Garden City
United Kingdom
Herts SG6 3TA

+44 01462 372472
Jo.Brady@dlrcgroup.com

Additional identifiers

Clinical Trials Information System (CTIS)
Nil known

Integrated Research Application System (IRAS)
1007602

ClinicalTrials.gov (NCT)
Nil known

Protocol serial number
IRAS 1007602

Study information

Scientific Title
Phase I trial: MM-120-101

Study objectives

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Ethics approval required
Ethics approval required

Ethics approval(s)
approved 18/09/2023, Wales Research Ethics Committee 1 Cardiff (Health and Care Research Wales, Castlebridge 4, 15-19 Cowbridge Road, East Cardiff, CF11 9AB, United Kingdom; 02922940912; wales.rec1@wales.nhs.uk), ref: 23/WA/0112

Study design
Phase 1 study in 30 healthy volunteers

Primary study design
Other

Study type(s)
Other, Safety

Health condition(s) or problem(s) studied
Healthy volunteers

Interventions

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Intervention Type

Drug

Phase

Phase I

Drug/device/biological/vaccine name(s)

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Primary outcome(s)

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Key secondary outcome(s)

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Completion date

19/12/2023

Eligibility**Key inclusion criteria**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Participant type(s)

Healthy volunteer

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Total final enrolment

0

Key exclusion criteria

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Date of first enrolment

13/10/2023

Date of final enrolment

04/12/2023

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre**MAC Clinical Research Liverpool**

11 Tiger Court
King's Business Park
Liverpool
England
L34 1BH

Study participating centre**MAC Clinical Research Manchester**

Citylabs 1.0
Nelson St
Manchester
England
M13 9NQ

Sponsor information**Organisation**

Mind Medicine Inc

Funder(s)

Funder type

Research organisation

Funder Name

Mind Medicine Inc

Results and Publications

Individual participant data (IPD) sharing plan**IPD sharing plan summary**

Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes